Understanding the determinants of myopic choroidal neovascularization and response to treatment



The pathophysiologic pathways that govern the development of choroidal neovascularization (CNV) are complex. Patchy atrophy and lacquer cracks are known to be major anatomic risk factors for the development of myopic CNV, but they are not alone and much remains to be understood about other factors that influence development. In addition, a greater understanding of the modifiable and nonmodifiable factors that influence outcome, resolution, and recurrence after intravitreal injection of anti-vascular endothelial growth factor (VEGF) could lead to more personalized treatment algorithms that integrate parameters other than the presence of CNV itself and could help improve clinical outcomes and reduce recurrence.


We reviewed recently published data on risk factors for CNV and predictors of response to anti-VEGF treatments. In particular, data pertaining to age, sex, genetic predisposition, baseline visual acuity, axial length, staphyloma, lacquer cracks, atrophic lesions, choroidal thickness or choroidal thinning, characteristics of CNV such as duration, localization, and size of CNV, and treatment considerations such as choice of treatment, loading doses, and combination treatments were reviewed.


Our analysis showed that the body of evidence is incomplete.


Additional studies are required to identify high-risk patients and to develop personalized therapeutic approaches.

Eur J Ophthalmol 2016; 26(6): 511 - 516

Article Type: REVIEW



Nicolas Leveziel, David Gaucher, Stéphanie Baillif, Xavier Benouaich, Claire Chartier, Thyphaine Grenet, Vincent Gualino, Valérie Krivosic, Marie Noelle Delyfer

Article History


Financial support: Supported by Novartis Pharma.
Conflict of interest: N. Leveziel: advisory board for Novartis, Allergan and Bayer. D. Gaucher: advisory board for Novartis, Allergan, and Bayer, who have funded congresses. S. Baillif: advisory board for Novartis and Bayer. X. Benouaich: Advisory board for Novartis. C. Chartier has been an employee of Novartis. T. Grenet: advisory board for Novartis and Bayer. V. Gualino: consultancy for Alcon, Allergan, Bayer, and Novartis. V. Krivosic: advisory board for Novartis and Bayer. M.N. Delyfer: advisory board for Novartis.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.



  •  Department of ophthalmology, CHU Poitiers, Poitiers - France
  •  New Civil Hospital, University Hospitals of Strasbourg, Strasbourg - France
  •  Laboratory of Bacteriology (EA-7290), Federation of Medicine Translational of Strasbourg, University of Strasbourg, Strasbourg - France
  •  Ophtalmology Department, University Hospital of Saint Roch, University of Nice Sophia Antipolis, Nice - France
  •  Clinic of Union, Union - France
  •  Novartis, Rueil-Malmaison - France
  •  Ophthalmic Imaging and Laser Center, Paris - France
  •  Honoré Cave Clinic, Montauban - France
  •  Department of Ophthalmology, University Hospital of Lariboisière, Paris Hospitals, Paris - France
  •  University Hospital of Toulouse, Purpan, Paule de Viguier, Toulouse - France
  •  Private Clinic and University Hospital of Lariboisière, Paris Hospitals, Paris - France
  •  Department of Ophtalmology, University Hospital of Bordeaux, Bordeaux - France
  •  Department of Ophthalmology, Pellegrin Hospital, Bordeaux - France
  •  University of Bordeaux, France-INSERM, ISPED, INSERM Center U897-Epidemiology Biostatistics, Bordeaux - France

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.